GlassScriptPhysician profile
Karthik Chamarti
NPI 1407464068
$970.68
in general payments reported to CMS, 2019-2025
12 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $669 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571 · Education: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.76 |
| Education | $399.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $299.93 | 2024 | |
| Aveo Pharmaceuticals, INC. | $166.75 | 2024-2025 | |
| Blueprint Medicines Corporation | $147.38 | 2024-2025 | Ayvakit |
| Incyte Corporation | $99.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.12 | 2025 | Alunbrig, Fruzaqla |
| Lilly USA, LLC | $51.84 | 2024 | |
| Beigene USA, INC. | $30.11 | 2024 | Brukinsa |
| Pfizer INC. | $27.16 | 2024 | |
| Daiichi Sankyo INC. | $27.04 | 2025 | Enhertu |
| Jazz Pharmaceuticals INC. | $24.38 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $24.22 | 2025 | Tagrisso |
| Myriad Genetic Laboratories, INC. | $11.76 | 2024 | Precisetumor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karthik Chamarti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.